COCP: Topline Data for Influenza A and Dual Coronavirus/Norovirus Programs Expected in 2024; Model Revision Leads to Valuation of $6 Per Share…

2d ago, source:

COCP READ THE FULL COCP RESEARCH REPORT Business Update Update on Influenza Program Cocrystal Pharma, Inc. (NASDAQ:COCP) is ...

Cocrystal Pharma Inc COCP

3d ago, source: Morningstar

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Cocrystal Pharma Reports 2023 Financial Results and Provides Updates on its Antiviral Drug-Development Programs

28d ago, source: Business Insider

March 28, 2024 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (Cocrystal or the Company) reports financial results for the 12 months ended December 31, 2023, and provides updates on its ...

Cocrystal Pharma Inc (COCP)

24d ago, source: Investing

Investing.com – U.S. stocks were mixed after the close on Wednesday, as gains in the Oil & Gas, Basic Materials and Telecoms sectors led shares higher while losses in the ...

Cocrystal Pharma, Inc.: Cocrystal Pharma Reports 2023 Financial Results and Provides Updates on its Antiviral Drug-Development Programs

28d ago, source: Finanznachrichten

March 28, 2024 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (Cocrystal or the Company) reports financial results for the 12 months ended December 31, 2023, and provides updates on its ...

Cocrystal Pharma Inc.

28d ago, source: Wall Street Journal

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Cocrystal Pharma Inc (COCP)

1mon ago, source: Investing

Cocrystal Pharma Inc (NASDAQ: COCP) reported preliminary results of a Phase 1 study with CC-42344, a broad-spectrum oral antiviral to treat pandemic and seasonal influenza A. The... Cocrystal Pharma ...